New data shows that the global market for POCT (Point Of Care Testing) increased significantly to about USD 34.6 billion in 2021 and is expected to increase annually by 7.9 percent to about USD 70.9 billion by 2030.
New data shows that the global market for POCT (Point Of Care Testing) increased significantly to about USD 34.6 billion in 2021 and is expected to increase annually by 7.9 percent to about USD 70.9 billion by 2030. 1 The Covid pandemic caused an increased demand for POCT in all market segments in 2020-2021. However, the market for POCT is expected to decline slightly in the near future, when the covid related cases decrease.2
The global market for bio-heart markers amounted to approximately USD 9.0 billion in 2021 and is expected to grow by approximately 9 percent per year until 2027. Thus, the estimated global market is expected to amount to approximately USD 14.9 billion in 2027.3
POCT for bio-heart markers is believed to be driven by an increased number of heart diseases globally and an increased awareness about the benefits of early diagnosis in order to be able to provide patients with fast and adequate care interventions.3
The main drivers of growth for POCT, execpt for the covid pandemic, are believed to be the increased need for diagnosis in developing countries, a growing number of laboratories with advanced diagnostic equipment in North America, rapid technological development, increased investment in research and development and an aging global population.2
The market for troponin amounted to USD 2.3 billion in 2017 and is expected to increase to USD 3.6 billion in 2022. This corresponds to an average annual growth of 8.9 percent.4
Prolight Diagnostics utvecklar tillsammans med dotterbolaget Psyros Diagnostics samt teknologipartners innovativa, flexibla, patientnära testsystem, Point Of Care Testing (POCT) som är baserad på patenterad teknik. POC-tester utförs utanför det traditionella sjukhuslaboratoriet med små mobila instrument på exempelvis vårdcentraler, äldreboende, akutmottagningar och intensivvårdsavdelningar, vilket möjliggör testning nära patienten och med snabba provsvar. Denna teknik kommer att innebära att vården i ett tidigt diagnosskede kan skilja ut de patienter som snabbt behöver vård från de patienter som exempelvis inte har hjärtinfarkt. Försäljningsvärdet inom POCT området uppgick 2021 till USD 34,6 miljarder och är i stark tillväxt. Bolagets aktier handlas under kortnamnet PRLD på marknadsplatsen NGM Nordic SME.
info@prolightdiagnostics.se
Gasverksgatan 3A
222 29 Lund (Sweden)
Tel: +46(0)73 582 39 87